3 articles
Dabur India forecasts double-digit consolidated revenue growth for the second quarter of fiscal 2027, indicating strong performance in its consumer goods segment.
The Delhi High Court granted Dabur India interim relief by staying an FSSAI order prohibiting food products with ambiguous '100%' claims. This allows the company to continue marketing its items pendin
The U.S. FDA issued an import alert for drugs produced at Dabur India's facility following inspections revealing data integrity lapses and hygiene violations. Dabur asserts domestic operations remain
ChemBrief